2-ethoxynaphthalene-1-carboxylic acid

We are 2-ethoxynaphthalene-1-carboxylic acid CAS:2224-00-2 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

Chemical Name:   2-ethoxynaphthalene-1-carboxylic acid
CAS.NO:2224-00-2
Molecular Formula:C13H12O3
Molecular Weight:216.23300

Synonyms:
2-ethyloxy-1-naphthalenecarboxylic acid
2-Ethoxy-1-naphthoic acid
2-ethoxy-1-naphthalenecarboxylic acid
2-ethoxy-naphthalene-1-carboxylic acid
2-Ethoxynaphthoic acid
2-ethoxynaphthalenecarboxylic acid
2-Ethoxy-1-naphthoicacid

Physical and Chemical Properties:
Density: 1.2±0.1 g/cm3
Boiling point: 398.7ºC at 760 mmHg
Melting point: 141-145 ° C
Flash point: 156.2ºC
Refractive index: 1.624

Specification:
Appearance:White  powder
Purity:≥99.0%
Residue on ignition:0.50%
Any other impurity:≤0.10%

Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:Store in a tightly closed container. Store in a cool, dry, well-ventilated area away from incompatible substances.
Application:2-Ethoxynaphthalene-1-carboxylic Acid is used in the synthesis of various antistaphylococcic penicillins.

Related News: “We will continue to closely monitor the situation and we look forward to reopening our stores as soon as possible.”2084-19-7 Onconova Therapeutics, Inc. and Inceptua Medicines Access (a business unit of the Inceptua Group) recently announced they have entered into a collaboration to make available intravenous rigosertib via a Pre-approval Access Program in selected countries around the world.11-bromo-13,13-dimethyl-13H-indeno[1,2-b]anthracene Onconova Therapeutics, Inc. and Inceptua Medicines Access (a business unit of the Inceptua Group) recently announced they have entered into a collaboration to make available intravenous rigosertib via a Pre-approval Access Program in selected countries around the world.117661-72-0 Onconova Therapeutics, Inc. and Inceptua Medicines Access (a business unit of the Inceptua Group) recently announced they have entered into a collaboration to make available intravenous rigosertib via a Pre-approval Access Program in selected countries around the world.Onconova Therapeutics, Inc. and Inceptua Medicines Access (a business unit of the Inceptua Group) recently announced they have entered into a collaboration to make available intravenous rigosertib via a Pre-approval Access Program in selected countries around the world.